Indicators on Clinical trial recruitment for ABBV-744 study You Should Know
In Section C, contributors will get ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Participants will get treatment until disorder progression or even the members are unable to tolerate the study drugs.Ubiquitin-associated proteins that regulate The soundness of vital Tremendous enhancer-mediated proteins ha